Belimumab in Remission of VASculitis

PHASE3CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

March 20, 2013

Primary Completion Date

February 6, 2017

Study Completion Date

February 6, 2017

Conditions
Vasculitis
Interventions
BIOLOGICAL

Placebo

Placebo

BIOLOGICAL

Belimumab 10 mg/kg

Belimumab 10 mg/kg

DRUG

Azathioprine

Azathioprine

Trial Locations (89)

4

GSK Investigational Site, Dublin

9

GSK Investigational Site, Dublin

1020

GSK Investigational Site, Brussels

1023

GSK Investigational Site, Budapest

1089

GSK Investigational Site, West Springfield

1090

GSK Investigational Site, Brussels

2107

GSK Investigational Site, Liverpool

2305

GSK Investigational Site, New Lambton

2605

GSK Investigational Site, Garran

3000

GSK Investigational Site, Leuven

3010

GSK Investigational Site, Bern

3144

GSK Investigational Site, Malvern

4032

GSK Investigational Site, Debrecen

4604

GSK Investigational Site, Kristiansand

7760

GSK Investigational Site, México

8006

GSK Investigational Site, Zurich

8036

GSK Investigational Site, Barcelona

9007

GSK Investigational Site, Sankt Gallen

10016

GSK Investigational Site, New York

10021

GSK Investigational Site, New York

10117

GSK Investigational Site, Berlin

11021

GSK Investigational Site, Great Neck

12808

GSK Investigational Site, Prague

12850

GSK Investigational Site, Prague

14021

GSK Investigational Site, Prague

14186

GSK Investigational Site, Stockholm

15261

GSK Investigational Site, Pittsburgh

16132

GSK Investigational Site, Genoa

19104

GSK Investigational Site, Philadelphia

19610

GSK Investigational Site, Wyomissing

20153

GSK Investigational Site, Milan

28034

GSK Investigational Site, Madrid

33604

GSK Investigational Site, Pessac

35033

GSK Investigational Site, Rennes

35294

GSK Investigational Site, Birmingham

36693

GSK Investigational Site, Mobile

40138

GSK Investigational Site, Bologna

42100

GSK Investigational Site, Reggio Emilia

43203

GSK Investigational Site, Columbus

48149

GSK Investigational Site, Münster

48202

GSK Investigational Site, Detroit

53226

GSK Investigational Site, Milwaukee

55905

GSK Investigational Site, Rochester

59037

GSK Investigational Site, Lille

60126

GSK Investigational Site, Torrette Di Ancona

60612

GSK Investigational Site, Chicago

66160

GSK Investigational Site, Kansas City

70124

GSK Investigational Site, Bari

70376

GSK Investigational Site, Stuttgart

72076

GSK Investigational Site, Tübingen

73230

GSK Investigational Site, Kirchheim unter Teck

75014

GSK Investigational Site, Paris

80336

GSK Investigational Site, München

85724

GSK Investigational Site, Tucson

91723

GSK Investigational Site, Covina

94030

GSK Investigational Site, Palo Alto

94578

GSK Investigational Site, San Leandro

97239

GSK Investigational Site, Portland

119992

GSK Investigational Site, Moscow

190068

GSK Investigational Site, Saint Petersburg

400006

GSK Investigational Site, Cluj-Napoca

02118-2307

GSK Investigational Site, Boston

08103-1438

GSK Investigational Site, Camden

L8N 4A6

GSK Investigational Site, Hamilton

M5T 3L9

GSK Investigational Site, Toronto

H1T 2M4

GSK Investigational Site, Montreal

H3G 1A4

GSK Investigational Site, Montreal

04103

GSK Investigational Site, Leipzig

07740

GSK Investigational Site, Jena

0372

GSK Investigational Site, Oslo

Callao 2

GSK Investigational Site, Callao

Lima 21

GSK Investigational Site, Lima

Lima 27

GSK Investigational Site, Lima

Lima 31

GSK Investigational Site, Lima

Lima 36

GSK Investigational Site, Lima

Lima 41

GSK Investigational Site, Lima

Lima14

GSK Investigational Site, Lima

80-952

GSK Investigational Site, Gdansk

40-635

GSK Investigational Site, Katowice

31-066

GSK Investigational Site, Krakow

20-954

GSK Investigational Site, Lublin

020125

GSK Investigational Site, Bucharest

Unknown

GSK Investigational Site, Stavropol

08025

GSK Investigational Site, Barcelona

RG1 5AN

GSK Investigational Site, Reading

AB25 2ZD

GSK Investigational Site, Aberdeen

CB2 0QQ

GSK Investigational Site, Cambridge

SE1 7EH

GSK Investigational Site, London

OX3 7LD

GSK Investigational Site, Oxford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Human Genome Sciences Inc., a GSK Company

INDUSTRY

NCT01663623 - Belimumab in Remission of VASculitis | Biotech Hunter | Biotech Hunter